Manuel Haschke
Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer
Hoemme A, Driessen C, Früh M, Thürlimann B, Wälti T, von Kameke A, Lehner C, Strasser F, Krähenbühl S, Haschke M, Barth H, Jörger M. Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer. Cancer Chemother Pharmacol 2019; 83:763-774.
Jan 25, 2019Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer
Jan 25, 2019Cancer Chemother Pharmacol 2019; 83:763-774
Hoemme Alexander, Driessen Christoph, Früh Martin, Thürlimann Beat, Wälti Thomas, von Kameke Alexander, Lehner Claudia, Strasser Florian, Krähenbühl Stephan, Haschke Manuel, Barth Holger, Jörger Markus
Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment
Parra-Guillen Z, Kloft C, Krähenbühl S, Gillessen Sommer S, Früh M, Pfister B, Winogradova D, Donzelli M, Haschke M, Berger P, Jörger M. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. Basic Clin Pharmacol Toxicol 2017; 121:309-315.
Jun 19, 2017Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment
Jun 19, 2017Basic Clin Pharmacol Toxicol 2017; 121:309-315
Parra-Guillen Zinnia P, Kloft Charlotte, Krähenbühl Stephan, Gillessen Sommer Silke, Früh Martin, Pfister Bogumila, Winogradova Daria, Donzelli Massimiliano, Haschke Manuel, Berger Peter B, Jörger Markus